BR112012014962A2 - métodos e composições para formulações líquidas e estáveis de fármacos - Google Patents

métodos e composições para formulações líquidas e estáveis de fármacos

Info

Publication number
BR112012014962A2
BR112012014962A2 BR112012014962A BR112012014962A BR112012014962A2 BR 112012014962 A2 BR112012014962 A2 BR 112012014962A2 BR 112012014962 A BR112012014962 A BR 112012014962A BR 112012014962 A BR112012014962 A BR 112012014962A BR 112012014962 A2 BR112012014962 A2 BR 112012014962A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
liquid
drug formulations
stable drug
Prior art date
Application number
BR112012014962A
Other languages
English (en)
Inventor
Crist J Frangakis
Harry J Leighton
Original Assignee
Exodos Life Sciences Ltd Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exodos Life Sciences Ltd Partnership filed Critical Exodos Life Sciences Ltd Partnership
Publication of BR112012014962A2 publication Critical patent/BR112012014962A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012014962A 2009-12-18 2010-12-17 métodos e composições para formulações líquidas e estáveis de fármacos BR112012014962A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28798809P 2009-12-18 2009-12-18
PCT/US2010/061135 WO2011075691A1 (en) 2009-12-18 2010-12-17 Methods and compositions for stable liquid drug formulations

Publications (1)

Publication Number Publication Date
BR112012014962A2 true BR112012014962A2 (pt) 2016-04-05

Family

ID=44167729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014962A BR112012014962A2 (pt) 2009-12-18 2010-12-17 métodos e composições para formulações líquidas e estáveis de fármacos

Country Status (10)

Country Link
US (2) US9629920B2 (pt)
EP (1) EP2512460A4 (pt)
JP (2) JP2013515004A (pt)
CN (1) CN102802617B (pt)
AU (1) AU2010330750B2 (pt)
BR (1) BR112012014962A2 (pt)
CA (1) CA2784826A1 (pt)
IL (1) IL220465A (pt)
RU (1) RU2589697C2 (pt)
WO (1) WO2011075691A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
WO2014008465A2 (en) * 2012-07-05 2014-01-09 The Research Foundation For The State University Of New York Potentiation of antibiotic treatment with a protein-lipid complex
US20160278899A1 (en) * 2013-11-05 2016-09-29 Synagile Corporation Devices and methods for continuous drug delivery via the mouth
US9326935B2 (en) * 2013-11-08 2016-05-03 Eli Lilly And Company Atomoxetine solution
US20170266106A1 (en) 2014-12-01 2017-09-21 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
WO2016179540A1 (en) 2015-05-06 2016-11-10 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
EP4242628A3 (en) * 2015-12-08 2023-11-08 Biomatrica, INC. Reduction of erythrocyte sedimentation rate
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN109212176B (zh) * 2018-08-30 2019-10-11 中拓生物有限公司 一种丙酮酸测定试剂盒及其制备方法和应用
JP2021536489A (ja) * 2018-09-05 2021-12-27 ベントリア、バイオサイエンス、インコーポレイテッドVentria Bioscience Inc. 免疫グロブリンａ製剤
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPS63215640A (ja) * 1987-03-04 1988-09-08 Nippon Hai Potsukusu:Kk 易吸収性抗炎症剤及びその製造方法
EP0326618A1 (en) 1987-03-04 1989-08-09 Nippon Hypox Laboratories Incorporated Medicinal composition containing albumin as carrier and process for its preparation
JPH05238947A (ja) * 1992-02-28 1993-09-17 Yakult Honsha Co Ltd 細菌毒素中和剤
DK0879604T3 (da) 1997-05-09 2003-08-04 Deutsches Krebsforsch Konjugat omfattende en folinsyreantagonist og en bærer
HU230338B1 (hu) * 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
JPH11258236A (ja) * 1998-03-09 1999-09-24 Sekisui Chem Co Ltd 抗リン脂質抗体測定試薬
EP1100494A1 (en) * 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
KR100675809B1 (ko) 1999-07-09 2007-02-01 오르토-맥네일 파마슈티칼, 인코퍼레이티드 맛을 차폐시킨 약제학적 액체 제제
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
CN103212084B (zh) 2003-11-13 2018-07-13 韩美科学株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
DE102004057196A1 (de) * 2004-11-26 2006-06-01 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR)
EA015277B1 (ru) * 2008-04-22 2011-06-30 Государственное Научное Учреждение "Институт Биоорганической Химии Национальной Академии Наук Беларуси" Конъюгат 28-норбрассинолида с бычьим сывороточным альбумином в качестве иммуногена
WO2011075688A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
CA2784785A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating inflammation of skin
DK2512479T3 (en) 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease

Also Published As

Publication number Publication date
EP2512460A4 (en) 2015-01-21
US20130071412A1 (en) 2013-03-21
AU2010330750B2 (en) 2015-10-01
WO2011075691A1 (en) 2011-06-23
AU2010330750A1 (en) 2012-08-02
CN102802617B (zh) 2016-05-11
IL220465A (en) 2017-03-30
CN102802617A (zh) 2012-11-28
US20170224834A1 (en) 2017-08-10
JP2013515004A (ja) 2013-05-02
CA2784826A1 (en) 2011-06-23
US9629920B2 (en) 2017-04-25
EP2512460A1 (en) 2012-10-24
JP2016053038A (ja) 2016-04-14
RU2589697C2 (ru) 2016-07-10
RU2012130391A (ru) 2014-01-27
IL220465A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
BR112012014962A2 (pt) métodos e composições para formulações líquidas e estáveis de fármacos
SMT201700008B (it) Composizione farmaceutica
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
SMT201400069B (it) Formulazione farmaceutica
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
DK3278665T3 (da) Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BR112012013148A2 (pt) formulação farmacêutica e uso
DK3246018T3 (da) Farmaceutisk sammensætning
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI1012539A2 (pt) composições farmacêuticas
BRPI1015939A2 (pt) composição farmacêutica
GT201200303A (es) Formulaciones farmacéuticas
EE201300005A (et) Ravimkoostis
IT1394400B1 (it) Composizioni farmaceutiche
BR112013011967A2 (pt) composição biodegradável para distribuição de fármaco
BRPI0921654A2 (pt) formulação farmacêutica
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI1011412A2 (pt) composição para liberação sustentada de droga compreendendo alutinante geopolimérico
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]